    Sentence 1: The U.S. Food and Drug Administration rejected  ImClone 's original application in December 2001 , saying the  trial had been sloppily conducted .    Sentence 2: The Food and Drug Administration ultimately  denied ImClone 's drug application in December 2001 , saying  that an Erbitux clinical trial was deficient .    